Pfizer’s ABRYSVO is a vaccine currently indicated in the United States for active immunization for the prevention of Lower Respiratory Tract Disease (LRTD) in individuals 18 through 59 years of age who are at increased risk for LRTD caused by Respiratory Syncytial Virus (RSV), individuals 60 and older and for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age. ABRYSVO is currently approved for use in the U.S. in adults 50-74 with certain underlying medical conditions (UMCs), adults 75 and older, and for maternal vaccination between 32 and 36 weeks of pregnancy. The Senior Director, Strategy and Performance Lead for ABRYSVO is accountable for formulating and implementing the U.S. strategic plan for ABRYSVO and managing brand performance dynamics across the brand, supply chain and major customer groups. This is a critical leadership position, responsible for establishing and owning implementation of a connected strategy across RSV, aligned with U.S. Vaccines and Pfizer Primary Care goals and performance objectives. As owner of the RSV strategic plan, the lead will coordinate across channel leads and cross functional partners to drive implementation through focused strategic initiatives and manage the operational agenda and performance reporting for the U.S. team on an ongoing basis. The role is additionally accountable for performance alignment and consistent reporting across adult and maternal RSV indications, coordinating investor and earnings reporting and playing a prominent role in coordinating ABRYSVO team and executive leadership engagements.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
5,001-10,000 employees